Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

David A. Palma, Robert Olson, Stephen Harrow, +19

The Lancet

Open-label TrialRadiation TherapyMedicineOligometastatic CancersStereotactic Ablative Radiotherapy +5

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

David A. Palma, Robert Olson, Stephen Harrow, +21

Journal of Clinical Oncology

Stereotactic body radiotherapy for colorectal liver metastases

Daniel T. Chang, Anand Swaminath, Margaret M. Kozak, +8

Cancer

The Canadian Association of Radiation Oncology Scope of Practice Guidelines for Lung, Liver and Spine Stereotactic Body Radiotherapy

Arjun Sahgal, David Roberge, Devin Schellenberg, +12

Clinical Oncology

Canadian AssociationRadiation TherapyRadiation Oncology ScopeMedicineRadiation Therapy Planning +7

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

David A. Palma, Robert Olson, Stephen Harrow, +22

BMC Cancer

Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes

Stephen Harrow, David A. Palma, Robert Olson, +19

International Journal of Radiation Oncology*Biology*Physics

Comprehensive TreatmentRadiation MedicineRadiopharmaceutical TherapyStereotactic RadiationRadiation Oncology +3

Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)

Shankar Siva, Alexander V. Louie, Andrew Warner, +13

Cancer

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

David A. Palma, Robert Olson, Stephen Harrow, +21

Surgical OncologyCancer ManagementOligometastatic CancersTreatment VerificationNeuro-oncology +18

Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study

Patrick Cheung, Samir Patel, Scott North, +17

European Urology

UrologyRadiation TherapyGenitourinary CancerMedicineProspective Multicenter Study +6

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

Robert Olson, Lindsay Mathews, Mitchell Liu, +21

BMC Cancer